Mitochondrial peptides like Humanin, MOTS-c, and MOCCI are small proteins that may help reduce inflammation and improve age-related health conditions. These peptides, derived from mitochondrial DNA, play a role in controlling inflammation, supporting mitochondrial function, and addressing cellular stress. Here's a quick summary of their key benefits:
- Humanin: Reduces inflammation by lowering cytokines (like IL-6 and TNF-α), protects cells from oxidative stress, and is linked to anti-aging effects.
- MOTS-c: Enhances metabolic regulation, improves insulin sensitivity, and activates antioxidant genes to manage stress.
- MOCCI: Modulates immune responses during infections and reduces mitochondrial stress.
Why it matters: Mitochondrial dysfunction and inflammation worsen with age, contributing to diseases like Alzheimer’s, cardiovascular issues, and inflammatory conditions. These peptides show potential in combating "inflammaging" and promoting longevity.
Challenges: Delivering these peptides effectively remains difficult due to low bioavailability and absorption issues. Emerging technologies, like nanoparticles and gene editing, aim to address these hurdles.
Mitochondrial peptides represent a growing area of research in inflammation and anti-aging science, with promising therapeutic applications for chronic diseases and age-related decline.
How Humanin Controls Inflammation
How Humanin Works in Inflammation Pathways
Humanin plays a role in controlling inflammation through several pathways. It interacts with various cell surface receptors, such as the gp130 subunit of the IL-6 receptor, ciliary neurotrophic factor receptor alpha (CNTFR), formylpeptide receptor-like-1 (FPRL-1), and WSX-1. This interaction enables Humanin to influence different aspects of the inflammatory response [2]. Specifically, Humanin reduces the production of pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α. It also binds to Bax, preventing it from activating inflammasomes, which helps limit the release of damage-associated molecular patterns (DAMPs) and activates STAT3 [2]. These mechanisms provide a foundation for exploring Humanin's potential in managing inflammatory conditions.
Clinical Studies on Humanin
Research has highlighted Humanin's anti-inflammatory effects across various diseases. For example, studies focusing on age-related macular degeneration (AMD) found that plasma Humanin levels were 36.58% lower in patients compared to healthy individuals. When retinal pigment epithelium (RPE) cells from AMD patients were treated with Humanin G, a more stable version of Humanin, there was a reduction in inflammatory markers like adhesion molecules and cytokines, including CD62E, TNF-α, and IL-1β [7, 9].
"In conclusion, we present novel findings that: A) show reduced Humanin protein levels in AMD plasma vs. normal plasma; B) suggest the role of inflammatory markers in AMD pathogenesis, and C) highlight the positive effects of Humanin G in reducing inflammation in AMD."
– Sonali Nashine et al. [4]
These findings align with research on inflammatory bowel disease (IBD), which also points to Humanin's anti-inflammatory potential. Studies showed that children with IBD had lower serum Humanin levels compared to healthy controls. Ex vivo experiments revealed that serum from IBD patients suppressed Humanin expression in cultured human growth plate specimens. However, treatment with the Humanin analog HNG prevented TNF-induced bone growth impairment [3].
"Our data showing suppressed serum humanin levels in IBD children with poor bone health provides the first evidence for a potential link between chronic inflammation and humanin regulation."
– Yunhan Zhao et al. [3]
Beyond these conditions, Humanin has shown protective effects in cardiovascular and metabolic diseases. For instance, it reduces oxidative stress in heart muscle cells by promoting the removal of damaged proteins and activating antioxidant enzymes through chaperone-mediated autophagy [2]. These benefits, combined with its anti-inflammatory properties, suggest that Humanin could play a role in broader health and longevity research.
Humanin for Anti-Aging and Longevity
The anti-inflammatory effects observed in various studies suggest that Humanin may help combat "inflammaging", a term used to describe chronic low-grade inflammation associated with aging. Research has shown that circulating Humanin levels are higher in long-lived Ames dwarf mice and lower in short-lived growth hormone transgenic mice, linking Humanin to lifespan regulation [2]. In neurodegenerative diseases like Alzheimer's, Humanin's interaction with IGFBP-3 (a protein involved in cell death) suggests it may help preserve cognitive function.
Humanin also influences crucial processes like autophagy, endoplasmic reticulum (ER) stress, energy metabolism, and oxidative stress, helping to counteract cellular decline. This multi-faceted approach aligns with current efforts to develop comprehensive strategies for promoting healthy aging.
At MASI Longevity Science, we integrate cutting-edge mitochondrial research to support our evidence-based approach to anti-aging. Our dedication to creating high-quality formulations is inspired by emerging studies on molecules like Humanin, which play a key role in cellular protection and longevity.
MOTS-c and MOCCI: Supporting Roles
MOTS-c: Managing Metabolic and Inflammatory Stress
MOTS-c plays a key role in managing mitochondrial and nuclear communication during stress. It moves to the nucleus and activates antioxidant and stress-response genes through the Folate-AICAR-AMPK pathway [6][7]. Found mainly in skeletal muscle and blood, its levels naturally decline with age [6].
This peptide influences energy metabolism, insulin sensitivity, and inflammation. In various inflammatory conditions - like sepsis, inflammatory pain, and acute lung injury - MOTS-c has been shown to improve survival rates, lower pro-inflammatory markers (TNF-α, IL-6, IL-1β), and boost anti-inflammatory IL-10 levels [6].
A 2025 study published in Redox Biology revealed MOTS-c's ability to protect against lung ischemia-reperfusion injury by triggering nuclear translocation and activating antioxidant genes. Notably, MOTS-c levels measured within 24 hours of cardiopulmonary bypass surgery outperformed traditional biomarkers in predicting acute respiratory distress syndrome, achieving an AUC of 0.885 [7].
While MOTS-c focuses on metabolic regulation, other mitochondrial-derived peptides (MDPs) contribute to refining immune responses, as described below.
MOCCI: Supporting Immune Responses
MOCCI plays a dual role in modulating inflammation. As a paralog of NDUFA4, it replaces this Complex IV subunit during inflammation, reducing mitochondrial membrane potential and reactive oxygen species (ROS) production. Additionally, its transcript produces miR-147b, which further suppresses immune responses [5].
MOCCI's translation levels can increase dramatically - up to 1,000-fold - after IL-1β stimulation [5]. The miR-147b microRNA targets NDUFA4 mRNA, achieving similar immune-suppressing effects while also boosting RIG-I/MDA-5-mediated antiviral immunity [5]. Research highlights that the C15ORF48 gene, which encodes MOCCI, becomes highly active during acute bacterial and viral infections, coordinating both peptide and microRNA actions to offer robust protection during these events [5].
How MDPs Work Together
These peptides form a sophisticated network that fine-tunes the body's response to inflammation and cellular stress. Building on Humanin's protective capabilities, MOTS-c focuses on addressing metabolic stress and activating antioxidant defenses, while MOCCI adjusts mitochondrial function during infections to regulate immune responses.
Each peptide operates through distinct mechanisms tailored to specific stressors. For example, MOTS-c activates protective gene programs during metabolic challenges, while MOCCI recalibrates mitochondrial activity during infections. Together, they help reduce oxidative stress, control inflammation, and maintain energy balance in cells. This multi-layered defense system highlights the potential of mitochondrial peptides as therapeutic tools for managing inflammation, combating age-related decline, and exploring new anti-aging treatments.
Therapeutic Uses and Current Challenges
Current Research and Early Studies
Mitochondrial-derived peptides are showing potential in addressing inflammatory conditions, with studies highlighting their protective effects across various diseases. For instance, in mouse models of ischemia-reperfusion, administering Humanin G either before or during reperfusion improved left ventricular function, reduced infarct size, and helped prevent cardiac arrhythmias. It also preserved mitochondrial function, which is critical for heart health [1].
Neurological research is equally promising. In Alzheimer’s disease models, intranasal administration of Humanin G (HNG) over three months significantly reduced Aβ accumulation, a hallmark of the disease, and improved cognitive performance [8].
Beyond the heart and brain, these peptides may also play a role in preventing hearing loss. Early studies suggest that both HNG and SHLP3 protect hair cells from gentamicin-induced toxicity, a common cause of hearing damage [9]. These findings hint at the wide-ranging therapeutic applications of mitochondrial-derived peptides. However, despite their potential, delivering these peptides effectively remains a significant hurdle.
Delivery and Absorption Problems
Turning mitochondrial peptides into practical treatments faces a major bottleneck: delivery and absorption. Oral administration is particularly challenging. The digestive system breaks down peptides quickly, and molecules larger than 700 Da struggle to be absorbed. On top of that, P-glycoproteins actively pump these molecules out of cells, leaving only about 1% bioavailability [10][11].
Their hydrophilic nature complicates things further, as they require carriers or chemical modifications to cross cellular membranes. Even advanced delivery systems like nanoparticles often encounter problems, such as low accumulation at target sites and unintended distribution throughout the body [12].
Targeting mitochondria specifically adds another layer of complexity. Therapeutic peptides must navigate both the outer and inner mitochondrial membranes, which is no small feat. Additionally, their thiol/disulfide structures can react with other compounds in the gastrointestinal tract, forming inactive conjugates that further reduce absorption [10][12].
Future Treatment Options
Despite these challenges, new technologies are emerging to improve delivery methods. Personalized medicine and gene-editing tools like CRISPR could refine mitochondrial peptide therapies by tailoring them to individual genetic profiles, potentially enhancing their effectiveness.
One promising approach involves mitochondria-targeted nanoparticle systems, such as those using the MITO-Porter mechanism. These systems employ fusogenic lipids and high-density peptides to improve cellular delivery while reducing off-target effects [12]. Microneedle technology is another innovative solution, creating tiny pores in the skin to bypass gastrointestinal barriers and improve drug absorption.
Researchers are also exploring next-generation targeting strategies. Developing new ligands and polymers with a natural affinity for mitochondria could minimize toxicity issues linked to current delivery methods. Nanoparticles smaller than 200 nm, for example, can move through mucus layers more efficiently, while polymeric nanoparticles provide better stability and controlled release compared to traditional liposomes [12].
Together, these advancements suggest that the current delivery challenges may soon be overcome, paving the way for mitochondrial peptides to transition from experimental compounds to effective treatments for inflammatory and other conditions.
sbb-itb-4f17e23
The Future of Humanin and Mitochondrial Peptides
Key Points About Humanin and Inflammation
Humanin, along with other mitochondrial-derived peptides, is emerging as a promising tool for managing inflammation and tackling age-related diseases. Studies reveal that Humanin levels naturally decline as we age, which makes supplementation an intriguing option, particularly as aging populations face heightened risks of chronic inflammation.
Research highlights Humanin's potential in treating conditions like Alzheimer's, stroke, diabetes, myocardial ischemia and reperfusion, atherosclerosis, amyotrophic lateral sclerosis (ALS), and even some cancers [15]. In age-related macular degeneration (AMD), for instance, patients have been found to exhibit elevated inflammatory markers alongside reduced Humanin levels, further solidifying its relevance in inflammation-related disorders.
A modified version of Humanin, known as Humanin G (HNG), has shown even greater anti-inflammatory properties. It works by reducing intracellular reactive oxygen species and maintaining mitochondrial function [14]. In AMD cell studies, HNG treatment has been found to lower key inflammatory proteins, such as CD62E/E-selectin, TNF-α, and various interleukins, offering a potential way to counteract inflammation driven by mitochondrial DNA damage [13]. These findings are paving the way for innovative approaches to combat inflammation in aging.
Impact on Longevity Science
Beyond its role in inflammation, Humanin and mitochondrial peptides are transforming the field of longevity research. Mitochondrial dysfunction is a key driver of "inflammaging" - the chronic, low-grade inflammation associated with aging. According to Pinchas Cohen, a leading researcher at USC:
"The discovery of microproteins that we made 25 years ago and have built upon now was a real, unique body of work that represents a new chapter in biology. It really changes how we look at genetics and transcriptomics and proteomics. It completely reshuffles the deck, if you will." [21]
The growing interest in therapeutic peptides is reflected in market projections, which estimate the industry will reach $68.83 billion by 2028 [18]. New delivery methods are also enhancing their practicality. For example, in Parkinson's disease models, intranasal administration of Humanin resulted in steady improvements in motor function, with effects increasing in a dose-dependent manner [16].
Mitochondrial peptides are becoming key players in longevity science by addressing critical aging processes such as mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, and loss of proteostasis [19]. Companies like MASI Longevity Science are combining cutting-edge research with anti-aging supplements to tackle these aging pathways.
The field is advancing at a rapid pace. Technologies like CRISPR gene editing and improved nanocarrier systems are making mitochondrial peptide therapies more accessible. For instance, a MOTS-c analog called CB4211 is currently in clinical trials for conditions like nonalcoholic steatohepatitis (NASH) and obesity [20]. Research also suggests that mitochondrial-derived peptide levels decrease with age and in cardiovascular diseases, pointing to their potential as both diagnostic markers and therapeutic targets [17].
As delivery systems improve and our understanding of these peptides deepens, therapies based on mitochondrial peptides like Humanin could play a central role in addressing inflammation, aging, and related diseases.
Mitochondrial-Derived Peptides in Aging and Related Diseases - Pinchas Cohen - RB2016
FAQs
How do mitochondrial peptides like Humanin, MOTS-c, and MOCCI help reduce inflammation and support healthy aging?
Mitochondrial peptides like Humanin, MOTS-c, and MOCCI play crucial roles in supporting cellular health, managing inflammation, and promoting healthier aging by reducing stress-related damage.
- Humanin works to control inflammation by blocking harmful inflammatory responses. It also encourages autophagy - a natural process where damaged cells are cleared out - helping maintain cellular repair and overall longevity.
- MOTS-c aids in balancing metabolism, which helps combat obesity and insulin resistance. Both of these are closely tied to chronic inflammation and the aging process.
- MOCCI boosts mitochondrial function and strengthens the body’s ability to handle cellular stress, which further helps in managing inflammation and supporting longevity.
These peptides are becoming a key area of interest in aging research, offering promising possibilities for improving both the quality and length of life.
What are the main challenges in using mitochondrial peptides like Humanin for therapy, and how are scientists addressing them?
Delivering mitochondrial peptides, like Humanin, for therapeutic purposes is no easy feat. The mitochondria’s double membrane and strong negative charge create significant barriers, often resulting in low absorption rates and unintended side effects.
To tackle these challenges, researchers are exploring cutting-edge delivery methods. Targeted nanocarriers and mitochondrial-targeting peptides are being developed to increase precision and minimize unwanted systemic effects. Additionally, techniques such as membrane fusion technology are being investigated to further enhance the efficiency of these treatments. These advancements could pave the way for using mitochondrial peptides to address inflammation and other conditions linked to aging.
How do mitochondrial peptides like Humanin help address age-related conditions such as Alzheimer's and heart disease?
Mitochondrial peptides, particularly Humanin, play an important role in defending against age-related conditions by protecting cells from stress and inflammation. Humanin stands out for its neuroprotective abilities, offering a shield for neurons against damage caused by amyloid-beta toxicity - one of the driving forces behind Alzheimer’s disease. Studies indicate that it may help maintain cognitive function and slow the progression of neurodegenerative disorders by boosting cellular resilience and metabolism.
When it comes to cardiovascular health, mitochondrial peptides work to reduce oxidative stress and inflammation - two major contributors to heart disease. They may help protect against issues like atherosclerosis and heart failure by enhancing the function of heart cells and minimizing cell death. These peptides show promise in tackling the root causes of age-related illnesses, opening up new possibilities for therapeutic developments.
